Loading
Life sciences · Journal article
Ejnmmi Research · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background 177 Lu-PSMA radiopharmaceutical therapy shows favorable clinical responses for metastatic castration-resistant prostate cancer patients but may cause radiation-induced kidney damage due to specific and nonspecific activity accumulation. We evaluated the association between cumulative kidney absorbed doses and long-term kidney toxicity. Methods This retrospective analysis included 127 patients who underwent treatment of mCRPC using 177 Lu-based ligands (7.4 GBq at each cycle for [ 177 Lu]Lu-PSMA-617 [ n = 25] or 3.6–9.5 GBq throughout the treatment for [ 177 Lu]Lu-PSMA-I&T [ n = 102]). MIM Software (7.3.4) was used to calculate the absorbed dose (AD) to the kidney (CT-based segmentation) using one of three validated protocols based on data availability: multiple timepoint acquisition, Hänscheid approach at 48 h, or the prior information approach. [ 99m Tc]Tc-MAG3 scintigraphy scans were used to obtain tubular excretion rates, while serum-based sampling for glomerular filtration rate (eGFR) quantification was used. Up to 36 months post-treatment initiation CTCAE v5.0: Chronic Kidney Disease was determined. Results The AD of [ 177 Lu]Lu-PSMA-617 (0.26 ± 0.09 Gy/GBq) was significantly less than [ 177 Lu]Lu-PSMA-I&T (0.32 ± 0.13 Gy/GBq) [ p = 0.01] at cycle 1. Kidney AD per cycle did not significantly change across treatment cycles for either [ 177 Lu]Lu-PSMA-617 (median change: cycle 1–2, 1%; 2–3, 7%; 3–4, −5%; 4–5, 8%; 5–6, 26%) or [ 177 Lu]Lu-PSMA-I&T (cycle 1–2, 0%; 2–3, 0%; 3–4, 0%; 4–5, 3%; 5–6, 5%), although patient numbers decreased with increasing cycles. The percent change in AD from cycle 1 to cycle 6 was 0.6% ± 34.1% [n=3] and 12.2% ± 32.8% [n=9] for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T, respectively. Cumulative AD exceeded 20 Gy in 5/127 (4%) patients, each who received at least 6 cycles of therapy. eGFR decrease was slightly greater in [ 177 Lu]Lu-PSMA-I&T than [ 177 Lu]Lu-PSMA-617; -13% [range: -76 – 40%] vs. -10% [range: -26 – 13%] at 24 months post-treatment. By 36 months post-treatment initiation of [ 177 Lu]Lu-PSMA-I&T, one patient reported CTCAE-3 and another CTCAE-4. 36 month follow-up of [ 177 Lu]Lu-PSMA-617 is unmatured. Conclusion Only 5/127 patients exceeded a kidney AD of 20 Gy, none developed CTCAE-3/4 nephrotoxicity. eGFR decrease was slightly greater in [ 177 Lu]Lu-PSMA-I&T than [ 177 Lu]Lu-PSMA-617, yet clinical repercussions is unknown. Radiation-induced nephrotoxicity remains rare within three-years.